Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)

BACKGROUND: Immune checkpoint inhibitors (ICIs) are currently the standard of care for metastatic urothelial cancer (mUC) after the failure of previous platinum-based chemotherapy. The choice of further therapy after ICI progression is a new challenge, and scarce data support it. We aimed to examine...

Full description

Saved in:
Bibliographic Details
Published in:Clin Med Insights Oncol
Main Authors: Bersanelli, Melissa, Buti, Sebastiano, Cortellini, Alessio, Bandini, Marco, Banna, Giuseppe Luigi, Pederzoli, Filippo, Farè, Elena, Raggi, Daniele, Giannatempo, Patrizia, De Giorgi, Ugo, Basso, Umberto, Losanno, Tania, Santini, Daniele, Mucciarini, Claudia, Tucci, Marcello, Tambaro, Rosa, Farnesi, Azzurra, Caffo, Orazio, Veccia, Antonello, Naglieri, Emanuele, Briganti, Alberto, Procopio, Giuseppe, Pignata, Sandro, Necchi, Andrea
Format: Artigo
Language:Inglês
Published: SAGE Publications 2021
Subjects:
Original Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8274126/
https://ncbi.nlm.nih.gov/pubmed/34290538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/11795549211021667
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items